Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker
- BOND RX™ Validated
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
5
(8 Reviews)
|
(18 Publications)
Rabbit Recombinant Monoclonal Microtubule-associated proteins 1A/1B light chain 3A antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Cited in 18 publications.
View Alternative Names
Microtubule-associated protein 1 light chain 3 alpha, Autophagy-related protein LC3 A, Autophagy-related ubiquitin-like modifier LC3 A, MAP1 light chain 3-like protein 1, Microtubule-associated proteins 1A/1B light chain 3A, MAP1A/MAP1B LC3 A, MAP1A/MAP1B light chain 3 A, MAP1LC3A
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker (AB52628)
Immunocytochemistry/ Immunofluorescence analysis of SH-SY5Y (human neuroblastoma epithelial cell) cells labeling MAP1LC3A with purified ab52628 at 1/100 dilution (10 μg/mL). Cells were fixed in 100% Methanol. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 μg/mL). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 μg/mL) dilution. DAPI (blue) was used as nuclear counterstain. ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 μg/mL) was used as the secondary antibody only control.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker (AB52628)
IHC image of ab52628 staining in human hippocampus formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab52628, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
- WB
Unknown
Western blot - Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker (AB52628)
All lanes:
Western blot - Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker (ab52628) at 1/50000 dilution
All lanes:
Fetal brain lysate at 10 µg
Secondary
All lanes:
goat anti-rabbit HRP labelled at 1/2000 dilution
Predicted band size: 14 kDa
Observed band size: 16 kDa
false
Related conjugates and formulations (2)
-
Anti-MAP1LC3A antibody [EP1528Y] - BSA and Azide free
-
HRP Anti-MAP1LC3A antibody [EP1528Y] - Autophagosome Marker
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (18)
Recent publications for all applications. Explore the full list and refine your search
World journal of gastrointestinal oncology 16:4716-4727 PubMed39678812
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular psychiatry 28:4622-4631 PubMed37723283
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed36769070
2023
Applications
Unspecified application
Species
Unspecified reactive species
British journal of pharmacology 178:2931-2947 PubMed33786819
2021
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 20:53-60 PubMed32565933
2020
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of allergy and clinical immunology 146:1210-1213.e9 PubMed32272130
2020
Applications
Unspecified application
Species
Unspecified reactive species
Drug design, development and therapy 14:395-405 PubMed32099325
2020
Applications
Unspecified application
Species
Unspecified reactive species
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 44:1291-1299 PubMed30575805
2018
Applications
Unspecified application
Species
Unspecified reactive species
The Prostate 78:95-103 PubMed29134671
2017
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 8:104347-104358 PubMed29262645
2017
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com